New drug combo targets Tough-to-Treat cancers in early trial
NCT ID NCT05661201
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-phase trial tests the safety of combining an experimental drug called NEROFE with the chemotherapy doxorubicin in people with advanced solid tumors that have a KRAS mutation and express the ST2 protein. About 24 participants whose cancer has progressed after standard treatments will receive weekly doses of both drugs. The main goal is to find the safest dose and watch for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEROFE and doxorubicin (chemotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have a KRAS mutation and ST2 protein.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so the main goal is safety, not effectiveness. The combination may cause significant side effects or fail to shrink tumors.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.